| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699467 | Clinical Oncology | 2008 | 6 Pages |
Abstract
The response rates achieved in this unselected cohort of patients are consistent with published data. The duration of tumour control is good, with most patients responding to imatinib mesylate for more than 2 years. Side-effects are mild and acceptable.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.W.Y. Wong, S.C. Lupton, L. Bhatt, L. Gross, P. Tanière, D.R. Peake, D. Spooner, J.I. Geh,